Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC20A2 | Q08357 | 1/20 | 1.00 |
| ▸ | SLC20A1 | Q8WUM9 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | USP8 | P40818 | 1/20 | 0.55 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.52 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.52 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.50 |
| ▸ | GPR27 | Q9NS67 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PLAU | P00749 | 2/20 | 0.49 |
| ▸ | PLAT | P00750 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7631719 | 0.93 | SLC20A2 (0.86) | SLC20A2SLC20A1USP2USP8MEN1 | |
| SCHEMBL7126685 | 0.91 | SLC20A2 (0.83) | SLC20A2SLC20A1USP2USP8SLC10A2 | |
| SCHEMBL7120286 | 0.85 | SLC20A2 (0.74) | SLC20A2SLC20A1SLC10A2SLC10A1SLC10A6 | |
| SCHEMBL12201483 | 0.84 | SLC20A2 (0.72) | SLC20A2SLC20A1USP2USP8MEN1 | |
| SCHEMBL6380677 | 0.83 | SLC20A2 (0.71) | SLC20A2SLC20A1USP2USP8MEN1 | |
| SCHEMBL7208743 | 0.82 | SLC20A2 (0.70) | SLC20A2SLC20A1USP2USP8AVPR2 | |
| SCHEMBL5110940 | 0.80 | SLC10A6 (0.68) | SLC20A2SLC20A1SLC10A2SLC10A1SLC10A6 | |
| SCHEMBL6862230 | 0.80 | SLC20A2 (0.66) | SLC20A2SLC20A1SLC10A2SLC10A1SLC10A6 | |
| SCHEMBL5115424 | 0.79 | SLC20A2 (0.66) | SLC20A2SLC20A1SLC10A2SLC10A1SLC10A6 | |
| SCHEMBL7128725 | 0.79 | SLC20A2 (0.66) | SLC20A2SLC20A1SLC10A2SLC10A1SLC10A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216449-A1 | Phosphate transport inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-11-20 | — | — | US | claimed |
| US-6458845-B1 | METHOD OF ANTAGONIZING A MACROPHAGE SCAVENGER RECEPTOR COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF AN N-PHENYL-2-(3-TRIFLUOROMETHYLPHENYLSULFONAMIDO)BENZAMIDE, A | SMITHKLINE BEECHAM CORPORATION | 2002-10-01 | — | — | US | claimed |
| EP-1202729-A1 | PHOSPHATE TRANSPORT INHIBITORS | SmithKline Beecham Corporation (US) | 2002-05-08 | — | — | EP | claimed |
| WO-2001098264-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-27 | — | — | WO | claimed |
| WO-2001087294-A1 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-22 | — | — | WO | claimed |
| WO-2001005398-A1 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-25 | — | — | WO | claimed |
| US-20030216449-A1 | Phosphate transport inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-11-20 | — | — | US | disclosed |
| EP-1187531-A4 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6458845-B1 | METHOD OF ANTAGONIZING A MACROPHAGE SCAVENGER RECEPTOR COMPRISING ADMINISTERING TO A SUBJECT IN NEED OF TREATMENT AN EFFECTIVE AMOUNT OF AN N-PHENYL-2-(3-TRIFLUOROMETHYLPHENYLSULFONAMIDO)BENZAMIDE, A | SMITHKLINE BEECHAM CORPORATION | 2002-10-01 | — | — | US | disclosed |
| EP-1202729-A1 | PHOSPHATE TRANSPORT INHIBITORS | SmithKline Beecham Corporation (US) | 2002-05-08 | — | — | EP | disclosed |
| EP-1187531-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2001098264-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001087294-A1 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001005398-A1 | PHOSPHATE TRANSPORT INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-01-25 | — | — | WO | disclosed |
| WO-2000078145-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216449-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC34A3 | SLC20A2 4/4885SLC20A1 5/4885USP2 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.